Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
US9920033B2 · kind B2 · utility
2Cited by
1References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 12, 2016 |
| Grant date | Mar 20, 2018 |
| Priority date | — |
| Expiry date | Nov 12, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a crystalline form of N-(3-fluoro-4-((7-(2-hydroxy-2-methylpropoxy)quinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide p-toluenesulfonate, the process for preparing the crystalline form thereof, and the pharmaceutical compositions comprising the crystalline form thereof. This invention also relates to a method of using such a crystalline form and pharmaceutical compositions comprising the crystalline form thereof in the treatment of hyperproliferative diseases in mammals, especially in humans.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.